Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
Claudia Seikrit, MD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
CKD-aP or Something Else? Decoding the Diagnosis
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Elevating CKD-aP Care: New Frontier
Lucio Manenti, MD, PhD
Kappa-Opioid Settings: Real-World Evidence Insights
CKD-aP Treatment Tool Kit
Leonie Kraft, MD
Potassium Binders: Safety Comes First!
Javed Butler, MD, MPH, MBA
Potassium Binders in Practice: Clinical Trial Evidence
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.